

Research Article

Synergistic Effect of MiR-146a Mimic and Cetuximab on Hepatocellular Carcinoma Cells

Suning Huang,¹ Rongquan He,² Minhua Rong,³ Yiwu Dang,⁴ and Gang Chen⁴

¹ Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, China
² Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, China
³ Research Department, Affiliated Cancer Hospital, Guangxi Medical University, 71 Hedi Road, Nanning, Guangxi Zhuang Autonomous Region 530021, China
⁴ Department of Pathology, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, China

Correspondence should be addressed to Gang Chen; chen.gang_triones@163.com

Received 1 November 2013; Revised 1 February 2014; Accepted 25 March 2014; Published 7 May 2014

Academic Editor: Wei Mike Liu

Copyright © 2014 Suning Huang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Previously, we found that the expression of microRNA-146a (miR-146a) was downregulated in hepatocellular carcinoma (HCC) formalin-fixed paraffin-embedded (FFPE) tissues compared to the adjacent noncancerous hepatic tissues. In the current study, we have explored the in vitro effect of miR-146a on the malignant phenotypes of HCC cells. MiR-146a mimic could suppress cell growth and increase cellular apoptosis in HCC cell lines HepG2, HepB3, and SNU449, as assessed by spectrophotometry, fluorimetry, and fluorescence microscopy, respectively. Furthermore, western blot showed that miR-146a mimic downregulated EGFR, ERK1/2, and stat5 signalings. These effects were less potent compared to that of a siRNA targeting EGFR, a known target gene of miR-146a. Moreover, miR-146a mimic could enhance the cell growth inhibition and apoptosis induction impact of various EGFR targeting agents. The most potent combination was miR-146a mimic with cetuximab, presenting a synergistic effect. In conclusion, miR-146a plays a vital role in the cell growth and apoptosis of HCC cells and inducing miR-146a level might be a critical targeted molecular therapy strategy for HCC.

1. Introduction

Hepatocellular carcinoma (HCC) represents a major form of primary liver malignancy in adults worldwide. The tumorigenesis and development of HCC is typical of a multistage process. Major risk factors for HCC include infection with HBV or HCV, alcoholic liver disease, and most probably nonalcoholic fatty liver disease [1–7]. The progression is considered to deregulate genes that are critical to biological cellular procedures such as cell cycle control, apoptosis, cell migration, and metastasis [8–15]. However, the sensitivity and specificity of these markers remain imperfect [15]. Therefore, new biomarkers are needed to help to understand the causes of hepatocarcinogenesis and to predict response possibilities towards different therapeutic methods.

The current therapies for HCC are challenged. New molecular therapies for HCC include epidermal growth factor receptor (EGFR) inhibitors, for instance, gefitinib, erlotinib [16, 17], cetuximab [18–21], and antiangiogenic compounds, such as bevacizumab [22, 23] and sunitinib [24]. In a phase III trial, patients with advanced HCC treated with the molecular targeted agent sorafenib had an increase in survival of approximately 3 months [25–29]. Nevertheless, new agents must be developed to treat advanced HCC.

MicroRNAs (miRs), small noncoding single-stranded RNAs of 19–24 nucleotides in length, negatively regulate the
expression of numerous target genes at the posttranscriptional and/or translational levels and play a vital role in the initiation and deterioration of HCC. Extensive profiling studies over the past several years have indicated that many miRNAs are abnormally expressed in HCC tissues [30–34]. Previously, we found that miR-146a expression was lower in HCC than that in their paracancerous liver tissues. The lower miR-146a expression was also related to advanced clinical TNM stage and distant metastasis [35]. In order to investigate the role of miR-146a on the malignant phenotypes of HCC cells, we performed *in vitro* experiments in the current study to explore the effect of miR-146a on the cell proliferation, viability, caspase-3/7 activity, apoptosis, and regulation of cellular signals in HCC cell lines Hep3B, HepG2, and SNU449. Furthermore, we studied the potential of miR-146a mimic as a therapeutic strategy by combining it and different EGFR target agents, including tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib, and monoclonal antibody cetuximab.

2. Materials and Methods

2.1. RT-qPCR. The total RNA including miRNA was isolated from HCC cells as reported [36–41]. Combination of RUN6B and let-7a was used as the housekeeping gene for the detection of miR-146a expression. GAPDH was used as internal reference for EGFR mRNA. The primers for miR-146a, RNU6B, and let-7a were included in TaqMan MicroRNA Assays (4427975, Applied Biosystems, Life Technologies Grand Island, NY, USA). Sequence of miR and references used in the paper were miR-146a (Applied Biosystems Cat. number 4427975-000468): UGAGAACUGAAUUGAUAUU; RNU6B (Applied Biosystems Cat. number 4427975-000468): UGAGAACUGAAUUGAUAUU; let-7a (Applied Biosystems Cat. number 4427975-000377): UGAGGGUGUAAGGU-UGUAUAGGU. The reverse primers were also used for the reverse transcription with TaqMan MicroRNA Reverse Transcription Kit (4366596, Applied Biosystems, Life Technologies Grand Island, NY, USA) in a total volume of 10 μL. Real-time qPCR for miRNA was performed with Applied Biosystems PCR7900. The alteration ratio of miR-146a was

\[
\text{ΔΔCq} = \frac{(1-1/2^{\text{ΔΔCq}})}{100} \times 100
\]

Real time RT-qPCR for EGFR was performed as reported [36, 38–41].

2.2. Inhibition and Reexpression of mir-146a in HCC Cells. The human HCC-derived cell lines HepG2 (HB-8065), HepB3 (HB-8064), and SNU449 (CRL-2234) were purchased from the American Type Culture Collection (ATCC, Rockville, MD, USA). They were cultured as previously described [42–44]. All *in vitro* experiments were performed in triplicate. HCC cells were planted in 24-well plates (2.5 \( \times 10^4 \) cells per well) or 96-well plates (2.5 \( \times 10^3 \) cells per well) and incubated at 37°C for 24 h. The cells were transfected with miR-146a inhibitor, miRNA inhibitor negative control, miR-146a mimic, and miRNA mimic negative control, respectively (Ambion, Life Technologies Grand Island, NY, USA) at a final concentration of 200 nmol/L for 96 h using combiMAGnetofection (OZ BIOSCIENCES, Marseille Cedex 9, France) in accordance with manufacturer’s procedure. MiRNA mimics are small, chemically modified double-stranded RNA molecules designed to specifically bind to and mimic endogenous miRNA molecules. They can enable miRNA functional analysis by upregulation of miRNA activity. MiRVana miRNA Mimic Negative Control Number 1 was used as miRNA mimic negative control in the current study and it is a random sequence miRNA mimic molecule that has been extensively tested in human cell lines and tissues and validated not to produce identifiable effects on known miRNA function. MiRNA inhibitors are chemically modified, single-stranded nucleic acids designed to specifically bind to and inhibit endogenous miRNA molecules. These ready-to-use inhibitors can be introduced into cells using transfection or electroporation parameters similar to those used for siRNAs. Anti-miR Negative Control Number 1 was used as inhibitor negative control in the present study and it is a random sequence anti-miR molecule that has been extensively tested in human cell lines and tissues and validated to produce no identifiable effects on known miRNA function. EGFR TKIs gefitinib, erlotinib, and EGFR-specific monoclonal antibody cetuximab (2 mg/mL, 13.719 μM) were purchased from Selleckchem, Munich, Germany. All agents were prepared as described previously [36–41]. The EGFR specific siRNA was described previously [36–39] (sequence: GCAAAGTGTGTAACGGAATAGGTAT). The EGFR specific siRNA was transfected into HCC cells with the same method as above.

2.3. Cell Biological Function Detections. Cell proliferation, cell viability, apoptosis and nuclear morphology, and caspase-3/7 activity were performed as described previously...
Figure 2: Time dependent effect of miR-146a on cell proliferation in HCC cell lines. HepG2, HepB3, and SNU449 cells (2.5 $\times$ 10^3 cells per well in 96-well plate) were cultured for 24 h and then transfected with miR-146a inhibitor, miR-146a mimic, EGFR siRNA, and their negative controls (200 nM) up to another 96 h. Cell proliferation was assessed per day with MTS assay (CellTiter 96 Aqueous One Solution Cell Proliferation Assay). *P < 0.05, **P < 0.01, compared to blank and negative controls at the same time point.
Figure 3: Time dependent effect of miR-146a on cell viability in HCC cell lines. HepG2, HepB3, and SNU449 cells (2.5 × 10³ cells per well in 96-well plate) were cultured for 24 h and then transfected with miR-146a inhibitor, miR-146a mimic, EGFR siRNA, and their negative controls (200 nM) up to another 96 h. Cell viability was monitored using fluorimetric detection of resorufin (CellTiter-Blue Cell Viability Assay). *P < 0.05, **P < 0.01, compared to blank and negative controls at the same time point.

[36–41, 43, 44] to study the effects of miR-146a inhibitor and miR-146a mimic. Western blot was performed as described previously [36–41, 43, 44]. The following primary antibodies were used: phospho-EGFR (Tyr1173, clone 9H2, Upstate), total-EGFR (2232, Cell Signaling Technology), phospho-AKT/PKB (pS473, Invitrogen), total-AKT (9272, Cell Signaling Technology), phospho-ERK1/2 (pTpY185/187, Invitrogen), total-ERK1/2 (9102, Cell Signaling Technology), phospho-stat5 (pY694, BD Biosciences), total-stat5 (9363, Cell Signaling Technology), caspase-3 (8G10, 9665, Cell Signaling Technology), and β-actin (Sigma-Aldrich N.V.).

2.4. Statistical Analysis. SPSS19.0 (Munich, Germany) was performed for statistical analysis. Results were representative of minimal three independent experiments unless stated otherwise. Values were presented as the mean ± standard deviation (SD). One-way analysis of variance (ANOVA) test was used to analyze significance between different groups. The least significant difference (LSD) method of multiple
Figure 4: Dose dependent effect of miR-146a on cell growth in HCC cell line HepG2. HepG2 cells (2.5 × 10^3 cells per well in 96-well plate) were cultured for 24 h and transfected with miR-146a inhibitor, miR-146a mimic, EGFR siRNA, and their negative controls with increasing concentrations for 96 h (0–200 nM). (a) Cell proliferation tested with MTS assay. (b) Cell viability detected using fluorimetric detection of resorufin (CellTiter-Blue Cell Viability Assay). *P < 0.05, **P < 0.01, compared to blank and negative controls with the same concentration.

comparisons between two groups was applied when the probability for ANOVA was statistically significant. Statistical significance was determined at a P < 0.05 level. In the analysis of additivity and synergism, the theoretical zero-interaction (exactly additive) dose-response curve for each miR-146a mimic + other agent combination was calculated by applying Bliss independence criterion [45] and was also assessed by the Biosoft CalcuSyn program (Ferguson, MO, USA). The combination index (CI) was used to express synergism (CI < 1), additive effect (CI = 1), or antagonism (CI > 1) [37, 38, 40, 41, 43, 46].

3. Results

3.1. MiR-146a Inhibited Cell Growth in HCC Cells. Transfection efficiency was first confirmed using real-time RT-qPCR (Figure 1). The effect of miR-146a on cell growth was detected using three independent assays, including MTS tetrazolium
Figure 5: Time dependent effect of miR-146a on cell caspase-3/7 activity in HCC cell lines. HepG2, HepB3, and SNU449 cells (2.5 × 10^3 cells per well in 96-well plate) were cultured for 24 h and then transfected with miR-146a inhibitor, miR-146a mimic, EGFR siRNA, and their negative controls (200 nM) up to another 96 h. Caspase-3/7 activity was detected using Apo-ONE Homogeneous Caspase-3/7 Assay.

3.2. MiR-146a Mimic Induced Apoptosis in HCC Cells. To validate whether miR-146a is able to influence apoptosis, the CellTiter-Blue assay was multiplexed with a fluorescent caspase-3/7 assay. The results showed that with the miR-146a inhibitor, caspase-3/7 activity was slightly less than the blank and negative controls, but indicated no significant
Figure 6: Time dependent effect of miR-146a on apoptosis in HCC cell lines. HepG2, HepB3, and SNU449 cells (2.5 × 10^3 cells per well in 96-well plate) were cultured for 24 h and then transfected with miR-146a inhibitor, miR-146a mimic, EGFR siRNA, and their negative controls (200 nM) up to another 96 h. Hoechst 33342/propidium iodide (PI) double fluorescent chromatin staining was used to analyze apoptosis. *P < 0.05, **P < 0.01, compared to blank and negative controls at the same time point.
Figure 7: Dose dependent effect of miR-146a on cell caspase-3/7 activity and apoptosis in HCC cell line HepG2. HepG2 cells (2.5 × 10³ cells per well in 96-well plate) were cultured for 24 h then transfected with miR-146a inhibitor, miR-146a mimic, EGFR siRNA, and their negative controls (0–200 nM) up to another 96 h. (a) Cellular apoptosis tested with Hoechst 33342/propidium iodide (PI) double fluorescent chromatin staining. (b) Cell caspase-3/7 activity detected using Apo-ONE Homogeneous Caspase-3/7 Assay. *P < 0.05, **P < 0.01, compared to blank and negative controls with the same concentration.

Figure 8: MiR-146a mimic suppressed cell growth and induced apoptosis with Hoechst 33342/propidium iodide (PI) double fluorescent chromatin staining. HepG2 cells (2.5 × 10³ cells per well in 96-well plate) were cultured for 24 h then transfected with miR-146a inhibitor, miR-146a mimic, EGFR siRNA, and their negative controls (200 nM) up to another 96 h. The effect on apoptosis was assessed and compared to mock and negative controls, ×200.
change. However, with the miR-146a mimic, caspase-3/7 activity was markedly enhanced in all three HCC cell lines tested (Figure 5) with a time and dose dependent manner. Similar to the result of cell growth, the effect of miR-146a on caspase activity was much milder than that of siRNA targeting EGFR. The time and dose dependent effect on apoptosis was confirmed microscopically by Hoechst 33342 and PI double fluorescent staining (Figures 6, 7 and 8).

3.3. Contribution of miR-146a in Relevant Cellular Signaling. To investigate the contribution of miR-146a in the regulation of cellular signaling, we examined the signaling of EGFR, AKT, ERK, and stat pathways by using western blot, which are related to cell survival, apoptosis, and invasion. These pathways were influenced little with miR-146a inhibitor transfection. However, the phospho-EGFR, phospho-ERK1/2, and phospho-stat5 were downregulated by miR-146a mimic 96 h after transfection, although weaker than EGFR siRNA (Figure 9).

3.4. Synergistic Effect of miR-146a Mimic and Cetuximab. EGFR is a confirmed target gene of miR-146a as previously reported [41, 47, 48]. We desired to explore the combinatorial effect of miR-146a mimic and agents targeting EGFR (small molecular inhibitors or monoclonal antibody), using the colorimetric MTS formazan proliferation assay and caspase activity assay. The inhibition of cell proliferation was much stronger with miR-146a mimic in combination with gefitinib, erlotinib, or cetuximab, compared to single drug or single miR-146a mimic in HepG2 cells (Figure 10). However, for gefitinib and erlotinib, the proliferation curve of the combinatorial treatment was not significantly higher than the Bliss independence curve, which indicated an additive effect. Surprisingly, the combination of miR-146a mimic and cetuximab showed an extremely higher inhibitory effect compared to the Bliss independence curve, which suggested a possible synergy in cell growth suppression (Figure 10). Furthermore, the combination of miR-146a mimic and cetuximab also gave a significantly higher caspase-3/7 signal than single treatment (Figure 11). In addition, western blot proved that with the combination of miR-146a mimic and cetuximab, the caspase-3 protein level was reduced and cleaved caspase-3 expression was increased (Figure 12). Meanwhile, the EGFR and downstream pathway signals were also further downregulated with miR-146a mimic combined with cetuximab, especially p-EGFR and p-ERK1/2 (Figure 13). To verify the additive or synergistic nature of combining EGFR targeted agents with the miR-146a mimic, a CI was calculated [37, 38, 40, 41, 45]. This unambiguously showed that the effect of gefitinib or erlotinib and miR-146a was additive (data not shown). With regard to the combination of cetuximab and miR-146a mimic, the effect was indeed entirely synergistic (Figure 14).

4. Discussion

Previously, we found that the relevant miR-146a expression in the HCC tissues and cultured cells was significantly lower than that in the adjacent noncancerous hepatic tissues. Moreover, miR-146a expression in early clinical stages (I and II) was remarkably higher than that in advanced stages (III and
IV). Lower level of miR-146a was also found in HCC patients with metastasis compared with those without metastasis [35]. These results strongly suggest that miR-146a acts as a tumor suppressor miRNA in HCC. To further explore the function of miR-146a on the malignant phenotypes of HCC cell, we performed a series of in vitro experiments.

We first investigated the contribution of miR-146a to cell growth and apoptosis in HCC cells and also compared the effect of miR-146a mimic to the siRNA specially targeting EGFR mRNA, since EGFR was documented as a target of miR-146a in various cancers [41, 47–50]. In the current study, the EGFR protein was downregulated in HCC HepG2 cells after transfection of miR-146a mimic, which implies that EGFR is a target of miR-146a in HCC. The miR-146a mimic decelerated the cell growth in all the cell lines tested (HepG2, HepB3, and SNU449), using three independent assays. Additionally, miR-146a mimic enhanced the caspase-3/7 activity and induced apoptosis in HCC cell lines. This could partially be explained by the downregulation of EGFR and the down-stream pathways as shown by western blot, especially ERK1/2.
Figure 11: miR-146a mimic increased the caspase-3/7 activity of cetuximab in HCC HepG2 cells. HepG2 cells (2.5 × 10^3 cells per well in 96-well plate) were cultured for 24 h then transfected with miR-146a mimic and negative control (200 nM). Meanwhile, cetuximab was added and the cells were cultured up to another 96 h. Caspase activity was performed as above. **P < 0.01, compared to agent alone of the same concentration.

Figure 12: Combination of miR-146a mimic and cetuximab induced more cleaved caspase-3 in HCC HepG2 cells. HepG2 cells (2.5 × 10^4 cells per well in 24-well plate) were cultured for 24 h then transfected with miR-146a mimic and negative control (200 nM). Meanwhile, cetuximab was added and the cells were cultured up to another 96 h. Western blot and signal intensity of the bands were shown. Antibodies include full length caspase-3, cleaved caspase-3, and β-Actin. M: mock control; C2: negative control for miRNA mimic; Mimi: miR-146a mimic; Cetu: cetuximab; comb: combination of miR-146a and cetuximab.
**Figure 13:** Effect of combining miR-146a mimic and cetuximab on EGFR and its downstream pathway signals in HCC HepG2 cells. HepG2 cells (2.5 × 10⁴ cells per well in 24-well plate) were cultured for 24 h then transfected with miR-146a mimic and negative control (200 nM). Meanwhile, cetuximab was added and the cells were cultured up to another 96 h. Western blot and signal intensity of the bands were shown. Antibodies included phospho-EGFR (p-EGFR), total-EGFR (t-EGFR), p-ERK1/2, t-ERK1/2, p-AKT, t-AKT, p-stat5, t-stat5, and β-Actin. M: mock control; Cetu: cetuximab; Mimi: miR-146a mimic; comb: combination of cetuximab and miR-146a mimic.

**Figure 14:** Combinational effect of cetuximab and miR-146a mimic in HepG2 cells. Cetuximab (0.001, 0.01, 0.1, 1, and 10 μM) was combined with miR-146a mimic (0.001, 0.025, 0.05, 0.1, and 0.2 μM) and cell proliferation was detected by MTS assay. Biosoft CalcuSyn program was used to calculate (a) median-effect plot, (b) dose-effect curve, and (c) CI. This indicates synergistic effect since CI < 1, (d) log₁₀( CI ).
and stat5, though HCC HepG2 expresses low level of p-stat5 at the basic line. However, the effect of miR-146a mimic on inhibiting cell growth and inducing apoptosis was much weaker than that of an EGFR-specific-siRNA. Since different mechanism could be involved in the process of EGFR gene silencing, probably much higher dosage of miR-146a mimic is needed to reach the same effect of EGFR siRNA. The miR-146a inhibitor had little effect on the function of HCC cells, which could be related to the limited downregulation of miR-146a level. With miR-146a inhibitor, the ∆∆Cq was about 2 times higher than the negative controls, in contrast with miR-146a mimic; the ∆∆Cq was about 9 times lower than the controls.

The suppressive role of miR-146a on the malignant phenotype of HCC cells makes it tempting to develop novel therapeutic strategies of inducing miR-146a levels. When we combined the miR-146a mimic together with different EGFR TKIs or cetuximab in HCC cells, miR-146a mimic was found to enhance the cell proliferation inhibition and apoptosis induction by TKIs and cetuximab, the strongest effect obtained when combined with cetuximab. Synergistic effect was obtained with the combination of miR-146a mimic and cetuximab. Western blot also confirmed that the EGFR, ERK1/2, and stat5 pathways were strongly inhibited with this combination. Since EGFR siRNA has stronger effect than miR-146a mimic, we wondered if the combination of EGFR siRNA and cetuximab could produce even more potent synergistic effect. Indeed, EGFR siRNA plus cetuximab have very powerful effect on cell growth inhibition and apoptosis induction (unpublished data on file). The level of miR-146a in cancer cells can also be upregulated by other agents. For example, Li et al. found that reexpression of miR-146a by nontoxic “natural agents,” including 3,3'-diindolylmethane, and isoflavone, has antitumor effects in pancreatic cancer [47].

5. Conclusions

Since miR-146a was found to be related to the HCC metastases, further in vitro studies are planned to identify the mechanism of miR-146a in metastasis. Other possible target genes of miR-146a, such as TRAF6, IRAK1, and NUMB, will also be tested. On the other hand, cell growth inhibition and apoptosis induction by miR-146a mimic represent great relevance due to its possible therapeutic potential. The application of miR-146a mimic might thus be a promising approach to HCC therapies in the future, for both in vivo studies and clinic trials.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Suning Huang and Rongquan He contributed equally.

Acknowledgments

The study was supported by the Fund of Guangxi Natural Scientific Research (no. 2010GXNSFB013059 and no. 2013GXNSFBA019191), Guangxi Provincial Health Bureau Scientific Research Project (Z2013201), and the Fund of National Natural Science Foundation of China (NSFC 81360327).

References

[1] M. Kudo, “Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy,” Oncology, vol. 81, supplement 1, pp. 1–10, 2011.
[2] M. Meguro, T. Mizuguchi, M. Kawamoto, and K. Hirata, “The molecular pathogenesis and clinical implications of hepatocellular carcinoma,” International Journal of Hepatology, vol. 2011, Article ID R88672, 8 pages, 2011.
[3] K. Yamazaki, Y. Masugi, and M. Sakamoto, “Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis,” Digestive Diseases, vol. 29, no. 3, pp. 284–288, 2011.
[4] R. Zemel, A. Issachar, and R. Tur-Kaspa, “The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma,” Clinics in Liver Dis ease, vol. 15, no. 2, pp. 261–279, 2011.
[5] M. Vertemati, C. Moscheni, D. Petrella et al., “Morphometric analysis of hepatocellular nodular lesions in HCV cirrhosis,” Pathology Research and Practice, vol. 208, no. 4, pp. 240–244, 2012.
[6] A. A. Abd, M. N. Al-AhdaI, S. S. Khalid et al., “IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection,” Hepatology International, vol. 7, pp. 533–538, 2013.
[7] H. Feng, J. Zhang, X. Li, and W. N. Chen, “HBX-Mediated migration of HBV-replicating HepG2 cells: insights on development of hepatocellular carcinoma,” Journal of Biomedicine and Biotechnology, vol. 2009, Article ID 930268, 6 pages, 2009.
[8] L. Hu, G. Chen, H. Yu, and X. Qiu, “Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma,” Hepatology International, vol. 4, no. 1, pp. 423–432, 2010.
[9] G. Chen and D. Luo, “Expression of decoy receptor 3 in liver tissue microarrays,” National Medical Journal of India, vol. 21, no. 6, pp. 275–278, 2008.
[10] G. Chen, Y.-W. Dang, D.-Z. Luo, Z.-B. Feng, and X.-L. Tang, “Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study,” Oncology Research, vol. 17, no. 4, pp. 183–189, 2008.
[11] G. Chen, D. Z. Luo, L. Liu, Z. B. Feng, F. Guo, and P. Li, “Hepatic local micro-environmental immune status in hepatocellular carcinoma and cirrhotic tissues,” West Indian Medical Journal, vol. 55, no. 6, pp. 403–408, 2006.
[12] G. Chen and D. Luo, “Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma,” Upsala Journal of Medical Sciences, vol. 113, no. 3, pp. 297–304, 2008.
[13] M. Yang, G. Chen, Y. Dang, and D. Luo, “Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients,” Upsala Journal of Medical Sciences, vol. 115, no. 4, pp. 232–237, 2010.
[14] Z. P. Ruan, R. Xu, Y. Lv et al., “PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib,” Oncology Research, vol. 20, no. 2–3, pp. 113–121, 2012.
[15] R. N. Aravalli, C. J. Steer, and E. N. K. Cressman, “Molecular mechanisms of hepatocellular carcinoma,” *Hepatology*, vol. 48, no. 6, pp. 2047–2063, 2008.

[16] P. A. Philip, M. R. Mahoney, C. Allmer et al., “Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer,” *Journal of Clinical Oncology*, vol. 23, no. 27, pp. 6657–6663, 2005.

[17] W. Tang, S. Weng, S. Zhang et al., “Direct interaction between surface betal, 4-galactosyltransferase 1 and epidermal growth factor receptor (EGFR) inhibits EGFR activation in hepatocellular carcinoma,” *Biochemical and Biophysical Research Communications*, vol. 434, pp. 449–454, 2013.

[18] H. K. Sanoff, S. Bernard, R. M. Goldberg et al., “Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma,” *Gastrointestinal Cancer Research*, vol. 4, no. 3, pp. 78–83, 2011.

[19] A. Asnacios, L. Fartoux, O. Romano et al., “Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study,” *Cancer*, vol. 112, no. 12, pp. 2733–2739, 2008.

[20] A. X. Zhu, K. Stuart, L. S. Blaszkowsky et al., “Phase II study of cetuximab, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma,” *Cancer*, vol. 110, no. 3, pp. 581–589, 2007.

[21] A. Huether, M. H¨opfner, V. Baradari, D. Schuppan, and H. Scher¨ubl, “EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer,” *Biochemical Pharmacology*, vol. 70, no. 11, pp. 1568–1578, 2005.

[22] M. B. Thomas, J. S. Morris, R. Chadha et al., “Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma,” *Journal of Clinical Oncology*, vol. 27, no. 6, pp. 843–850, 2009.

[23] A. X. Zhu, L. S. Blaszkowsky, D. P. Ryan et al., “Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma,” *Journal of Clinical Oncology*, vol. 24, no. 12, pp. 1898–1903, 2006.

[24] S. Fairev, E. Raymond, E. Boucher et al., “Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study,” *The Lancet Oncology*, vol. 10, no. 8, pp. 794–800, 2009.

[25] D. H. Palmer, “Sorafenib in advanced hepatocellular carcinoma,” *The New England Journal of Medicine*, vol. 359, no. 23, pp. 2498–2499, 2008.

[26] M. S. Copur, “Sorafenib in advanced hepatocellular carcinoma,” *The New England Journal of Medicine*, vol. 359, no. 23, pp. 2498–2499, 2008.

[27] G. Spinzi and S. Paggi, “Sorafenib in advanced hepatocellular carcinoma,” *The New England Journal of Medicine*, vol. 359, no. 23, pp. 2498–2499, 2008.

[28] J. M. Llovet, A. M. di Biscaglie, J. Bruix et al., “Design and endpoints of clinical trials in hepatocellular carcinoma,” *Journal of the National Cancer Institute*, vol. 100, no. 10, pp. 698–711, 2008.

[29] J. M. Llovet, S. Ricci, V. Mazzaferro et al., “Sorafenib in advanced hepatocellular carcinoma,” *The New England Journal of Medicine*, vol. 359, no. 4, pp. 378–390, 2008.

[30] C. Augello, V. Vaira, L. Caruso et al., “MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma,” *Liver International*, vol. 32, no. 5, pp. 772–782, 2012.

[31] M. Negrini, L. Gramantieri, S. Sabbioni, and C. M. Croce, “microRNA involvement in hepatocellular carcinoma,” *Anti-Cancer Agents in Medicinal Chemistry*, vol. II, no. 6, pp. 500–521, 2011.

[32] F. Sato, E. Hatano, K. Kitamura et al., “MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan criteria,” *PLoS ONE*, vol. 6, no. 1, Article ID e16435, 2011.

[33] S. Diao, J.-F. Zhang, H. Wang et al., “Proteomic identification of microRNA-122a target proteins in hepatocellular carcinoma,” *Proteomics*, vol. 10, no. 20, pp. 3723–3731, 2010.

[34] J. Burchard, C. Zhang, A. M. Liu et al., “MicroRNA-122 as a regulator of mitochondrial metabolic gene network in hepatocellular carcinoma,” *Molecular Systems Biology*, vol. 6, article 402, 2010.

[35] M. Rong, R. He, Y. Dang, and G. Chen, “Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues,” *Upsala Journal of Medical Sciences*, vol. 119, no. 1, pp. 19–24, 2014.

[36] G. Chen, P. Kronenberger, E. Teugels, and J. De Grève, “Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells,” *Biological Procedures Online*, vol. 13, no. 1, article 1, 2011.

[37] G. Chen, P. Kronenberger, E. Teugels, I. A. Umelo, and J. De Grève, “Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab,” *BMC Medicine*, vol. 10, article 28, 2012.

[38] G. Chen, P. Kronenberger, E. Teugels, I. A. Umelo, and J. De Greve, “Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents,” *Biochemical and Biophysical Research Communications*, vol. 431, pp. 623–629, 2013.

[39] G. Chen, P. Kronenberger, I. A. Umelo, E. Teugels, and J. De Grève, “Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction,” *Analytical Biochemistry*, vol. 398, no. 2, pp. 266–268, 2010.

[40] G. Chen, A. Noor, P. Kronenberger, E. Teugels, I. A. Umelo, and J. De Grève, “Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib,” *PLoS ONE*, vol. 8, Article ID e59708, 2013.

[41] G. Chen, I. A. Umelo, S. Lv et al., “miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells,” *PLoS ONE*, vol. 8, Article ID e60317, 2013.

[42] G. Chen, M. Rong, and D. Luo, “TNFRSF6b neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell,” *Pathology Research and Practice*, vol. 206, no. 9, pp. 631–641, 2010.

[43] Y. Dang, D. Luo, M. Rong, and G. Chen, “Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET,” *PLoS ONE*, vol. 8, Article ID e61054, 2013.

[44] M. Rong, G. Chen, and Y. Dang, “Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro,” *BMC Cancer*, vol. 13, article 21, 2013.

[45] R. Koivusalo, E. Krausz, H. Helenius, and S. Hietsen, “Chemotherapy compounds in cervical cancer cells primed
by reconstitution of p53 function after short interfering RNA-mediated degradation of human papillomavirus 18 E6 mRNA: opposite effect of siRNA in combination with different drugs,” Molecular Pharmacology, vol. 68, no. 2, pp. 372–382, 2005.

[46] T.-C. Chou, “Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies,” Pharmacological Reviews, vol. 58, no. 3, pp. 621–681, 2006.

[47] Y. Li, T. G. Vanden Boom II, Z. Wang et al., “miR-146a suppresses invasion of pancreatic cancer cells,” Cancer Research, vol. 70, no. 4, pp. 1486–1495, 2010.

[48] B. Xu, N. Wang, X. Wang et al., “MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer,” Prostate, vol. 72, pp. 1171–1178, 2012.

[49] D. Bhaumik, G. K. Scott, S. Schokrpur, C. K. Patil, J. Campisi, and C. C. Benz, “Expression of microRNA-146 suppresses NF-κB activity with reduction of metastatic potential in breast cancer cells,” Oncogene, vol. 27, no. 42, pp. 5643–5647, 2008.

[50] J. Mei, R. Bachoo, and C.-L. Zhang, “MicroRNA-146a inhibits glioma development by targeting Notch1,” Molecular and Cellular Biology, vol. 31, no. 17, pp. 3584–3592, 2011.